Indiana, Illinois, Iowa Foundation for Fair Contracting names, public group, project, contractor of the year
This year's honorees are:
Public Body of the Year: City of Moline
Moline has been selected as the Public Body of the Year to recognize its outstanding commitment to advancing infrastructure and community development through collaboration with top-tier responsible contractors.
Project of the Year: Rebuild Downtown Rock Island Redevelopment• Project Owner: City of Rock Island• General Contractor: Valley Construction• Project Engineer: V&K• Project Architect: Streamline Architects• Project Advocate: The Rock Island Downtown Alliance
The redevelopment project is being recognized for showing innovation and collaboration in revitalizing downtown Rock Island to benefit businesses and residents for generations to come. This project will kick-start Rock Island's future as a destination hub for the entire Quad Cities.
Contractor of the Year: Central Excavating
The company is being recognized for outstanding work in the construction industry, a commitment to hiring and training a skilled workforce and adherence to fair contracting standards.
'We are proud to recognize these exceptional partners who demonstrate integrity, quality and commitment to the public good,' said Andrew Waeyaert, Regional Manager at III FFC. 'Their contributions ensure that taxpayer dollars are invested wisely while delivering high-quality, lasting infrastructure improvements in the Quad Cities.'
The III FFC's Annual Construction Industry & Public Official Appreciation Dinner is a way to celebrate achievements in public works construction while strengthening collaboration among industry leaders, contractors and public officials.
The III FFC is a nonprofit construction industry foundation that increases market share for responsible contractors, work opportunities for skilled craftworkers and value for taxpayers through a comprehensive program of procurement oversight, jobsite monitoring, market analysis and public policy education. Click here for more on the Indiana, Illinois, Iowa Foundation for Fair Contracting.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
a few seconds ago
- Bloomberg
Jeep Cherokee Resurrected as Hybrid SUV to Reverse Sales Slump
Stellantis NV is bringing back the Jeep Cherokee as a bigger, electrified SUV after a nearly three-year hiatus, plugging a crucial hole in its US lineup as it seeks to reverse a sales slump and navigate a market whipsawed by tariffs. Jeep is trying to claw back share in the SUV market after six consecutive years of US sales declines. Former Stellantis Chief Executive Officer Carlos Tavares temporarily discontinued the Cherokee in 2023 as part of a plan to move production from Illinois to Mexico.
Associated Press
an hour ago
- Associated Press
AbbVie Completes Acquisition of Capstan Therapeutics
NORTH CHICAGO, Ill., Aug. 19, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie. Capstan's lead asset CPTX2309, currently in Phase 1 for the treatment of B cell-mediated autoimmune diseases, is a tLNP that generates CD19-specific, CD8+ in vivo CAR-T cells. The CAR-T cells are designed to achieve rapid and deep B cell depletion with the aim of achieving durable, drug-free remission. This can be accomplished without the need for lymphodepleting chemotherapy, while also avoiding other challenges associated with conventional ex vivo CAR-T therapies. 'With the acquisition now complete, we are excited to work together with the talented team at Capstan to advance our mission of transforming patient care,' said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. 'The addition of CPTX2309 and Capstan's tLNP platform strengthens our ability to deliver new treatments aimed at resetting the immune system and enables application of Capstan's proprietary technology more broadly for in vivo programming of cells.' For additional background on the acquisition, please read the press release announcing the definitive agreement under which AbbVie will acquire Capstan here. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter), and YouTube. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, 'Risk Factors,' of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. View original content to download multimedia: SOURCE AbbVie
Associated Press
2 hours ago
- Associated Press
Pivot Bio, Soil and Water Outcomes Fund Partner to Expand Acres
Partnership makes use of Pivot Bio's nitrogen-fixing products an eligible practice under SWOF sustainability programs MINNEAPOLIS, Aug. 21, 2025 /PRNewswire/ -- Pivot Bio, one of the most innovative agtech companies in the world, announced a strategic partnership with the Soil and Water Outcomes Fund (SWOF). This collaboration will enable farmers in Indiana and Illinois to use Pivot Bio's proprietary gene-edited nitrogen-fixing technology, PROVEN® 40 and PROVEN® G3 corn products, while participating in one of sustainable agriculture's most farmer-friendly programs. The partnership connects Pivot Bio's proven solutions with SWOF's extensive network of partners, including major food and agriculture companies seeking verified environmental outcomes in their supply chains. By incorporating Pivot Bio's products and reducing usage of synthetic fertilizer, SWOF participants can leverage a biologically fixed nitrogen source to achieve measurable reductions in greenhouse gas emissions and nitrogen runoff, while maintaining or improving yield performance. 'This partnership with SWOF represents a natural evolution of our sustainability program, N-OVATOR®, which is helping to transform nitrogen management in the U.S.,' said Lori Reese, head of commercial sustainability at Pivot Bio. 'Replacing a portion of synthetic nitrogen with Pivot's proprietary biological nitrogen in combination with other SWOF eligible practices, such as reduced tillage and cover cropping, will create unprecedented opportunities for our customers to maximize both environmental impact and economic returns.' The collaboration builds on the strong momentum Pivot Bio has built through its sustainability initiatives. Since 2022, Pivot Bio's N-OVATOR program has paid over $13 million to farmers for verified nitrogen replacement, with 1.4 million acres enrolled in the program in 2024 alone. SWOF's outcomes-based approach pays farmers an average of $33 per acre for implementing conservation practices. SWOF and Pivot Bio run separate, independent sustainability programs, and growers may participate in only one of these programs for the same acres in a given year. Last year, farmers using Pivot Bio products typically reduced synthetic nitrogen use by 37+ pounds per acre while achieving a 16% improvement in nitrogen-use efficiency. By selecting SWOF enrollment, growers can unlock revenue streams, turning their environmental impact into measurable economic value. 'Our products already make nitrogen management more predictable and profitable for farmers. Now, through SWOF, they can be rewarded for the water quality improvements and emissions reductions,' said Reese. 'This partnership exemplifies how cutting-edge agricultural technology and outcomes-based conservation programs can work together to accelerate the transition to more sustainable farming systems.' SWOF's Adam Kiel added, 'Fertilizer management is key to achieving emission reductions in agriculture. Providing more solutions to farmers will help achieve meaningful environmental outcomes at scale.' The partnership takes effect immediately. Pivot Bio products are now available to order for the 2026 season to optimize both agronomic performance and ecosystem service payments. About Pivot Bio Pivot Bio, one of the world's leading innovative agtech companies, delivers to farmers patented crop nutrition technologies that harness the power of nature to reliably and productively grow the food the world needs in the face of increasing volatility. Currently available in North America and soon in Brazil, the company's products are a breakthrough innovation and one of the agriculture industry's most promising climate solutions. Pivot Bio has been recognized three times by TIME magazine on its annual list of best inventions, by Fast Company on its World Changing Ideas and World's 50 Most Innovative Companies lists, by CNBC on its Disruptor 50 list of private companies, by Fortune on its Impact 20 list of startups driving social good and by MIT Tech Review as one of 15 climate tech companies to watch. About the Soil and Water Outcomes Fund The Soil and Water Outcomes Fund (SWOF) provides financial incentives to farmers for implementing on-farm conservation practices that yield positive environmental outcomes such as carbon sequestration and water quality improvement. SWOF provides new market opportunities and revenue streams for farmers through partnerships with public and private beneficiaries that purchase the environmental outcomes. SWOF has enrolled more than 1.7 million acres across 21 states since 2020. The SWOF is managed by AgOutcomes, a subsidiary of the Iowa Soybean Association. View original content to download multimedia: SOURCE Pivot Bio, Inc
